Literature DB >> 26514813

A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus.

Cynthia Aranow1.   

Abstract

The Physician Global Assessment (PGA) is an important and useful outcome measurement of lupus disease activity, but consensus on whether the PGA should be performed prior to or after the receipt of laboratory values is lacking. The objective of this study was to collect preliminary data on the optimal time to perform a PGA. In this pilot study, a PGA was performed by a single clinician upon completion of an outpatient clinical encounter and again after receipt of pertinent laboratory values. Laboratory values obtained at each clinical visit included a CBC, comprehensive chemistries, C3, C4, anti-dsDNA antibody levels, urinalysis and, if pertinent, a spot urinary protein/creatinine ratio. Disease activity was additionally determined by the SELENA-SLEDAI. Fifty-four patients, 3 males and 51 females with an average SLE disease duration of 12.3 (SD 10.5) years contributed 74 assessments to this study. The average SELENA-SLEDAI was 2.2. The average pre-laboratory PGA was 0.46, and the average post-laboratory PGA was 0.55 (p < 0.02 paired Student's t test). Among the 48 encounters with active disease and a mean SELENA-SLEDAI of 3.37, concordance of the pre-laboratory and post-laboratory PGAs occurred in only third of the patient encounters. Both pre- and post-PGA correlated with the SELENA-SLEDAI. However, the correlation of the post-PGA with the SELENA-SLEDAI was significantly greater than the correlation of the pre-PGA and SELENA-SLEDAI [r = 0.69 vs 0.79, respectively (p < 0.0179)]. In some lupus patients, the PGA determined prior to receipt of laboratory values may be the same as the PGA determined after laboratory values are received. However, in these preliminary data, there was a significant difference between pre-laboratory and post-laboratory PGA with a significantly greater correlation of the post-laboratory PGA with the SELENA-SLEDAI. Further studies in a larger patient population with a greater range of disease activity are needed to confirm and extend these findings.

Entities:  

Keywords:  Disease activity; Outcomes; Systemic lupus erythematosus

Mesh:

Year:  2015        PMID: 26514813     DOI: 10.1007/s12026-015-8712-7

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  10 in total

1.  Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus.

Authors:  S C Bae; H K Koh; D K Chang; M H Kim; J K Park; S Y Kim
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

4.  Validity and reliability of lupus activity measures in the routine clinic setting.

Authors:  M Petri; D Hellmann; M Hochberg
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

5.  Combined oral contraceptives in women with systemic lupus erythematosus.

Authors:  Michelle Petri; Mimi Y Kim; Kenneth C Kalunian; Jennifer Grossman; Bevra H Hahn; Lisa R Sammaritano; Michael Lockshin; Joan T Merrill; H Michael Belmont; Anca D Askanase; W Joseph McCune; Michelene Hearth-Holmes; Mary Anne Dooley; Joan Von Feldt; Alan Friedman; Mark Tan; John Davis; Mary Cronin; Betty Diamond; Meggan Mackay; Lisa Sigler; Michael Fillius; Ann Rupel; Frederick Licciardi; Jill P Buyon
Journal:  N Engl J Med       Date:  2005-12-15       Impact factor: 91.245

6.  Systemic lupus erythematosus disease activity index 2000.

Authors:  Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

7.  The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

Authors:  E M Hay; P A Bacon; C Gordon; D A Isenberg; P Maddison; M L Snaith; D P Symmons; N Viner; A Zoma
Journal:  Q J Med       Date:  1993-07

Review 8.  Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE.

Authors:  C Vitali; W Bencivelli; D A Isenberg; J S Smolen; M L Snaith; M Sciuto; R Neri; S Bombardieri
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

9.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

Authors:  M H Liang; S A Socher; M G Larson; P H Schur
Journal:  Arthritis Rheum       Date:  1989-09

10.  Comparison of the systemic lupus erythematosus activity questionnaire and the systemic lupus erythematosus disease activity index in a black barbadian population.

Authors:  Kim R Quimby; Cindy Flower; Ian R Hambleton; R Clive Landis; Anselm J M Hennis
Journal:  Int J Rheumatol       Date:  2013-10-24
  10 in total
  3 in total

Review 1.  New therapeutic strategies in systemic lupus erythematosus management.

Authors:  Mariele Gatto; Margherita Zen; Luca Iaccarino; Andrea Doria
Journal:  Nat Rev Rheumatol       Date:  2019-01       Impact factor: 20.543

2.  Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Authors:  Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

Review 3.  Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?

Authors:  Ioannis Parodis; Paul Studenic
Journal:  J Clin Med       Date:  2022-01-11       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.